Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms.

Ans PauwelsKarlien RaymenantsAnnelies GeeraertsVeerle BoecxstaensImke MasuyCharlotte BroersTim VanuytselJan Tack

Published in: Alimentary pharmacology & therapeutics (2022)

Baclofen decreases several reflux parameters in PPI refractory GERD symptoms, but pH-impedance monitoring is necessary before treatment as only SAP+ patients experience clinical benefit after 4 weeks.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
open label
chronic kidney disease
prognostic factors
double blind
peritoneal dialysis
protein protein
randomized controlled trial
magnetic resonance
phase ii
depressive symptoms
bone marrow
patient reported
replacement therapy